23029019|t|PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.
23029019|a|Emerging strategies that center upon the mammalian target of rapamycin (mTOR) signaling for neurodegenerative disorders may bring effective treatment for a number of difficult disease entities. Here we show that erythropoietin (EPO), a novel agent for nervous system disorders, prevents apoptotic SH-SY5Y cell injury in an oxidative stress model of oxygen-glucose deprivation through phosphatidylinositol-3-kinase (PI 3-K)/protein kinase B (Akt) dependent activation of mTOR signaling and phosphorylation of the downstream pathways of p70 ribosomal S6 kinase (p70S6K), eukaryotic initiation factor 4E-binding protein 1 (4EBP1), and proline rich Akt substrate 40 kDa (PRAS40). PRAS40 is an important regulatory component either alone or in conjunction with EPO signal transduction that can determine cell survival through apoptotic caspase 3 activation. EPO and the PI 3-K/Akt pathways control cell survival and mTOR activity through the inhibitory post-translational phosphorylation of PRAS40 that leads to subcellular binding of PRAS40 to the cytoplasmic docking protein 14-3-3. However, modulation and phosphorylation of PRAS40 is independent of other protective pathways of EPO that involve extracellular signal related kinase (ERK 1/2) and signal transducer and activator of transcription (STAT5). Our studies highlight EPO and PRAS40 signaling in the mTOR pathway as potential therapeutic strategies for development against degenerative disorders that lead to cell demise.
23029019	0	6	PRAS40	Gene	84335
23029019	46	60	erythropoietin	Gene	2056
23029019	61	65	mTOR	Gene	2475
23029019	137	166	mammalian target of rapamycin	Gene	2475
23029019	168	172	mTOR	Gene	2475
23029019	188	215	neurodegenerative disorders	Disease	MESH:D019636
23029019	308	322	erythropoietin	Gene	2056
23029019	324	327	EPO	Gene	2056
23029019	348	372	nervous system disorders	Disease	MESH:D009422
23029019	393	400	SH-SY5Y	CellLine	CVCL:0019
23029019	445	451	oxygen	Chemical	MESH:D010100
23029019	452	459	glucose	Chemical	MESH:D005947
23029019	480	509	phosphatidylinositol-3-kinase	Gene	5295
23029019	519	535	protein kinase B	Gene	2185
23029019	537	540	Akt	Gene	207
23029019	566	570	mTOR	Gene	2475
23029019	631	654	p70 ribosomal S6 kinase	Gene	6198
23029019	656	662	p70S6K	Gene	6198
23029019	716	721	4EBP1	Gene	1978
23029019	728	761	proline rich Akt substrate 40 kDa	Gene	84335
23029019	763	769	PRAS40	Gene	84335
23029019	772	778	PRAS40	Gene	84335
23029019	852	855	EPO	Gene	2056
23029019	927	936	caspase 3	Gene	836
23029019	949	952	EPO	Gene	2056
23029019	968	971	Akt	Gene	207
23029019	1007	1011	mTOR	Gene	2475
23029019	1082	1088	PRAS40	Gene	84335
23029019	1126	1132	PRAS40	Gene	84335
23029019	1168	1174	14-3-3	Gene	10971
23029019	1219	1225	PRAS40	Gene	84335
23029019	1273	1276	EPO	Gene	2056
23029019	1327	1334	ERK 1/2	Gene	5595;5594
23029019	1390	1395	STAT5	Gene	6776
23029019	1420	1423	EPO	Gene	2056
23029019	1428	1434	PRAS40	Gene	84335
23029019	1452	1456	mTOR	Gene	2475
23029019	1525	1547	degenerative disorders	Disease	MESH:D019636
23029019	Association	MESH:D019636	2056
23029019	Association	2475	84335
23029019	Association	207	84335
23029019	Association	MESH:D019636	2475
23029019	Positive_Correlation	2056	2475
23029019	Association	2056	207
23029019	Association	207	2475
23029019	Association	2475	5295
23029019	Bind	10971	84335
23029019	Association	2056	6198
23029019	Association	MESH:D009422	2056
23029019	Association	2056	5594
23029019	Positive_Correlation	836	84335
23029019	Association	2056	84335
23029019	Association	2185	2475
23029019	Association	2056	5595
23029019	Association	MESH:D019636	84335
23029019	Association	2056	6776
23029019	Association	2056	836
23029019	Negative_Correlation	MESH:D005947	MESH:D010100

